Dergiler / Journal of the Turkish-German Gynecological Association / 2017 / Cilt: 18 - Sayı: 1

Pharmacokinetic, pharmacodynamic, and clinical aspects of ovulation induction agents: A review of the literature

Sayfa
48–55
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this review, we evaluate the current literature to determine the most reliable and relevant information about the most used ovulation induction drugs. (J Turk Ger Gynecol Assoc 2017; 18: 48-55)

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Controlled ovarian hyperstimulation is a key step for successful outcomes of assisted reproductive technique cycle outcomes.
📊
Temel Bulgular & Veri:Many medications are available, which are commonly useed solely or in combination to achieve multiple follicular development.
💡
Sonuç & Katkı:In this review, we evaluate the current literature to determine the most reliable and relevant information about the most used ovulation induction drugs. (J Turk Ger Gynecol Assoc 2017; 18: 48-55)
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2017 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Controlled ovarian hyperstimulation is a key step for successful outcomes of assisted reproductive technique cycle outcomes. Many medications are available, which are commonly useed solely or in combination to achieve multiple follicular development. Pharmacokinetic, pharmacodynamic, and clinical information of ovulation induction drugs deserve to be elucidated for every individual patient before commencing infertility treatment. New concepts and new treatment protocols are introduced as ovulation physiology is understood by infertility specialists. Increasing treatment success by minimizing aderse effects is a milestone of all ovarian stimulation protocols that use these novel interventions. Achievement of a satisfactory cycle outcome includes retrieval of sufficient oocytes, a single clinical pregnancy, and avoidance of ovarian hyperstimulation syndrome. In this review, we evaluate the current literature to determine the most reliable and relevant information about the most used ovulation induction drugs. (J Turk Ger Gynecol Assoc 2017; 18: 48-55)

🔖

Bu Makaleye Atıf Yap

YILMAZ, B., KAHYAOĞLU, S., IŞIK, A. Z. (2022). Pharmacokinetic, pharmacodynamic, and clinical aspects of ovulation induction agents: A review of the literature. Journal of the Turkish-German Gynecological Association, Cilt: 18 - Sayı: 1, 48–55. https://ajindex.com/articles/567520

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (6)

  1. Gülekli B, Göde F, Sertkaya Z, Isık AZ. Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series. J Turk Ger Gynecol Assoc 2015; 16: 35-40.
  2. Humaidan P, Kol S, Papanikolaou EG; Copenhagen GnRH Agonist Triggering Workshop Group. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 2011; 17: 510-24.
  3. Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005; 20: 2887-92.
  4. George K, Kamath MS, Nair R, Tharyan P. Ovulation triggers in anovulatory women undergoing ovulation induction. Cochrane Database Syst Rev 2014: CD006900. Youssef MA, Abou-Setta AM, Lam WS. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev 2016: CD003719. Youssef MA, Al-Inany HG, Aboulghar M, Mansour R, Abou-Setta AM. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev 2011: CD003719. Chang P, Kenley S, Burns T, Denton G, Currie K, DeVane G, et al. Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization-embryo transfer. Fertil Steril 2001; 76: 67-74. Mahmoud Youssef MA, van Wely M, Aboulfoutouh I, El-Khyat W, van der Veen F, Al-Inany H. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis. Fertil Steril 2012; 97: 876-85.
  5. Pouwer AW, Farquhar C, Kremer JA. Long-acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database Syst Rev 2015: CD009577. Fauser BC, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BM, et al. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reprod Biomed Online 2010; 21: 593-601.
  6. Humaidan P, Schertz J, Fischer R. Efficacy and Safety of Pergoveris in Assisted Reproductive Technology--ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergo